Medscape has featured research by Dr. Truong-An (Andrew) Ho, a Pulmonary and Critical Care Fellow at the Temple Lung Center, focusing on the impact of biologic therapies in patients with chronic obstructive pulmonary disease (COPD) and T2 inflammation. The findings were presented at the ERS Congress.
The study examined patients with COPD and T2 inflammation who received biologic treatments. It found that individuals showing improvements in perimeter-adjusted internal perimeter 10 (Pi10) and airway wall percentage (WA%) on quantitative CT scans also had statistically significant gains in forced expiratory volume in one second (FEV1). According to Dr. Ho’s presentation, “Extended follow-up showed a trend toward reduced low attenuation area percentage (%LAA), fewer hospitalizations and fewer mean exacerbations per year, suggesting a longer duration may be needed to detect structural changes induced by biologics that target T2 inflammation.”
These results suggest that while certain lung function markers improve following biologic treatment, further observation over time is likely required to fully assess structural changes within the lungs.
